A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

被引：9
|
作者：
LoRusso, Patricia
Gounder, Mrinal M.
Patel, Manish R.
Yamamoto, Noboru
Bauer, Todd Michael
Laurie, Scott
Grempler, Rolf
Davenport, Teffany
Geng, Junxian
Rohrbacher, Maren
Lahmar, Mehdi
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3016
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Schoeffski, P.
    Yamamoto, N.
    Bauer, T.
    Patel, M.
    Gounder, M. M.
    Geng, J.
    Sailer, R.
    Jayadeva, G.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S743 - S743
  • [2] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
    Gounder, M.
    Patel, M. R.
    Yamamoto, N.
    Bauer, T. M.
    Laurie, S.
    Perez-Pitarch, A.
    Geng, J.
    Cheng, J.
    Lahmar, M.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1124 - S1125
  • [3] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Bauer, Todd Michael
    Schoffski, Patrick
    Grempler, Rolf
    Durland-Busbice, Sara
    Geng, Junxian
    Maerten, Angela
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
    LoRusso, Patricia
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott A.
    Bauer, Todd M.
    Geng, Junxian
    Davenport, Teffany
    Teufel, Michael
    Li, Jian
    Lahmar, Mehdi
    Gounder, Mrinal M.
    CANCER DISCOVERY, 2023, 13 (08) : 1802 - 1813
  • [5] A phase Ia/Ib, open label, multicenter, dose -escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
    Chong, Curtis Robert
    Bauer, Todd Michael
    Laurie, Scott Andrew
    Patel, Manish R.
    Yamamoto, Noboru
    Davenport, Teffany
    Geng, Junxian
    Gibson, Neil
    Vallaster, Markus P.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
    LoRusso, Patricia
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Bauer, Todd Michael
    Geng, Junxian
    Sailer, Reinhard
    Tang, Yuefen
    Jayadeva, Girish
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
    Tolcher, Anthony W.
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony G.
    Lahmar, Mehdi
    Wang, Bushi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
    Schoeffski, P.
    Lorusso, P.
    Yamamoto, N.
    Lugowska, I.
    Garcia, V. Moreno
    Lauer, U.
    Hu, C.
    Jayadeva, G.
    Lahmar, M.
    Gounder, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S472 - S473
  • [9] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
    Yamamoto, Noboru
    Hafez, Navid
    Tolcher, Anthony W.
    Teufel, Michael
    Geng, Junxian
    Svensson, Liz
    Lahmar, Mehdi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Efficacy and safety of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials
    Macarulla, Teresa
    Yamamoto, Noboru
    Tolcher, Anthony W.
    Hafez, Navid
    Lugowska, Iwona
    Ramlau, Rodryg
    Geng, Junxian
    Li, Jian
    Teufel, Michael
    Maerten, Angela
    Lorusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 487 - 487
12345